Telix Pharmaceuticals is trading at $9.65, up 4.18% in pre-market, with no fresh material company announcement identified to explain the October 29 move. - The latest investor update was the October 21 Q3 report. - Healthcare was up 1.32% pre-market, providing a supportive sector backdrop, though it does not establish the specific cause of Telix Pharmaceuticals’ larger gain. - Recent director share purchases have been reported, but their connection to this morning’s move is unconfirmed.